Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory

Cesar Rodriguez, MD; Yvonne A. Efebera, MD; Natalia Neparidze, MD; and Omar Nadeem, MD, examine how treatment approaches for transplant-ineligible/deferred newly diagnosed multiple myeloma are evolving through clinical trials like CEPHEUS, IMROZ, and BENEFIT, which demonstrate improved outcomes with anti–CD38-based quadruplet regimens while considering factors such as MRD negativity, administration methods, and patient selection criteria for optimizing therapeutic strategies.

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

December 24th 2024

Panelists discuss how current treatment approaches for transplant-ineligible newly diagnosed multiple myeloma patients are evolving with the addition of anti-CD38 therapies to standard VRd backbone, while examining unmet needs and the role of MRD negativity as an endpoint through recent trial data including CEPHEUS.

EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

January 3rd 2025

Panelists discuss how recent trials evaluating quadruplet regimens in transplant-ineligible/deferred NDMM, including IMROZ and BENEFIT, demonstrate promising efficacy with isatuximab-VRd combinations showing comparable MRD negativity rates to CEPHEUS’ daratumumab-VRd data, though cross-trial comparisons require careful interpretation.

EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

January 7th 2025

Panelists discuss how patient selection for quadruplet therapy in transplant-ineligible/deferred NDMM requires careful consideration of multiple factors, including fitness level and comorbidities, while highlighting daratumumab-VRd’s potential advantages such as subcutaneous administration and demonstrated efficacy in the CEPHEUS trial despite increased complexity and cost considerations.

EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

January 14th 2025

Panelists discuss how the future treatment landscape for transplant-ineligible/deferred NDMM is evolving toward more personalized approaches with quadruplet regimens, while acknowledging remaining challenges in optimizing duration of therapy, managing toxicities, and improving access to novel combinations.

EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM

January 21st 2025

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.

EP. 6: Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM

January 28th 2025

Panelists discuss the challenges and barriers that remain when considering early referral for chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (R/R MM).

EP. 7: Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

February 4th 2025

Panelists discuss their optimal strategies for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T in the treatment of relapsed/refractory multiple myeloma (R/R MM).

EP. 8: Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

February 4th 2025

Panelists discuss the latest efficacy data from the CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM), the significance of minimal residual disease (MRD) negativity, and how real-world and patient-reported outcomes influence the decision to use chimeric antigen receptor (CAR) T-cell therapy for early-stage R/R MM. They also compare standard-of-care idecabtagene vicleucel (ide-cel) and cilta-cel in this patient population.

EP. 9: CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

February 11th 2025

Panelists discuss how recent data from the KarMMa-3 study inform the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), including insights from the updated analysis.

EP. 10: Weighing CAR T Toxicity Profiles in Early R/R MM

February 11th 2025

Panelists discuss how recent data from the KarMMa-3 study influence the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), as well as the key toxicities considered when selecting chimeric antigen receptor (CAR) T-cell therapy. They also explore how these toxicities impact the transition of patients back to the community setting post CAR T and share strategies for managing early- and late-stage toxicities.

EP. 11: The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma

February 18th 2025

Panelists discuss the key toxicities influencing chimeric antigen receptor (CAR) T-cell therapy selection for early relapsed/refractory multiple myeloma (R/R MM), the transition to community care post treatment, strategies for managing toxicities, the future of CAR T in early R/R MM, and the impact of emerging data on treatment sequencing, along with insights from the DREAMM-7 and DREAMM-8 studies and improving the CAR T process in academic and community settings.

EP. 12: Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma

February 18th 2025

Panelists provide a high-level overview of the treatment landscape for later-stage relapsed/refractory multiple myeloma (R/R MM), discussing the latest therapies and emerging treatment options for this patient population.

EP. 13: Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

February 25th 2025

Panelists comment on recent updates from the International Myeloma Society/ American Society of Hematology (IMS/ASH) 2024 annual meetings, discussing the efficacy of approved bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM), including teclistamab (MajesTEC-1), elranatamab (MagnetisMM-3), and talquetamab (MonumenTAL-1).

EP. 14: Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

February 25th 2025

Panelists briefly discuss the results of studies evaluating additional bispecific regimens in the later-stage relapsed/refractory multiple myeloma space, including cevostamab, ABBV-383 plus daratumumab-dexamethasone (Dd), and linvoseltamab in the LINKER-MM1 trial.

EP. 15: Future Treatment Considerations for Multiple Myeloma

March 4th 2025

Panelists discuss how they approach sequencing therapy for relapsed/refractory multiple myeloma, considering all approved and investigational agents, and the factors that guide their treatment choices. They also explore the future directions of the later-stage relapsed/refractory multiple myeloma space, time permitting.

x